Immuno-Oncology | Specialty

Dr. Chiang Discusses Ipilimumab Plus Nivolumab in Small Cell Lung Cancer

August 10th 2017

Anne Chiang, MD, PhD, professor and thoracic oncologist at Yale Cancer Center, discusses ipilimumab (Yervoy) plus nivolumab (Opdivo) in small cell lung cancer.

Dr. Cohen on Challenges with Immunotherapy in Head and Neck Cancer

August 9th 2017

Ezra Cohen, MD, associate director, Moores Cancer Center at the University of California, San Diego, discusses challenges with immunotherapy in head and neck cancer.

Dr. Lallas on Ongoing Trials Investigating Immunotherapy for GU Cancer

August 8th 2017

Costas Lallas, MD, professor at Sidney Kimmel Medical College, Thomas Jefferson University Hospital, discusses ongoing trials investigating immunotherapy regimens for patients with genitourinary malignancies.

Dr. Chowdhury on Sequencing of Immunotherapy Regimens for RCC

August 8th 2017

Simon Chowdhury, PhD, MA, MBBS, MRCP, consultant medical oncologist specializing in urological cancer, Sarah Cannon Research Institute, United Kingdom, discusses sequencing of immunotherapy regimens for patients with renal cell carcinoma (RCC).

Sequencing Switches, Intriguing Combos Being Debated in ALK+ NSCLC

August 8th 2017

Joel Neal, MD, discusses the latest therapeutic changes to the ALK-positive NSCLC armamentarium.

Dr. Black Discusses Immunotherapy Biomarkers in Bladder Cancer

August 8th 2017

Peter Black, MD, senior research scientist, Vancouver Prostate Centre, associate professor, Department of Urologic Sciences, University of British Columbia, discusses immunotherapy biomarkers in bladder cancer.

Dr. Gupta Discusses Adjuvant Immunotherapy in Kidney Cancer

August 8th 2017

Shilpa Gupta, MD, assistant professor, Hematology Oncology and Transplantation Division, University of Minnesota, discusses adjuvant immunotherapy in kidney cancer.

Dr. Burtness on Challenges Facing Immunotherapy in Head and Neck

August 7th 2017

Barbara Burtness, MD, professor of medicine, Yale Cancer Center, discusses challenges regarding immunotherapy for patients with head and neck cancer.

Dr. Choueiri on Trials Investigating Combination Regimens for RCC

August 7th 2017

Toni K. Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses trials investigating combinations for patients with renal cell carcinoma (RCC).

Wakelee Shares Latest on Immunotherapy Agents, EGFR Inhibitors in Lung Cancer

August 4th 2017

Heather Wakelee, MD, discusses the latest developments with EGFR inhibitors and immunotherapy agents in non-small cell lung cancer.

Choueiri Discusses Avelumab/Axitinib, Other Novel RCC Combos

August 4th 2017

Toni Choueiri, MD, reflects on avelumab/axitinib results and other emerging combos in RCC.

Dr. Rini on the Efficacy of Axitinib and Pembrolizumab in RCC

August 4th 2017

Brian I. Rini, MD, professor of medicine, Cleveland Clinic, discusses the efficacy of pembrolizumab (Keytruda) and axitinib (Inlyta) combined in patients with renal cell carcinoma (RCC).

Dr. Rosenberg on Immunotherapy in Non-Metastatic Muscle Invasive Bladder Cancer

August 3rd 2017

Jonathan E. Rosenberg, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses immunotherapy in patients with non-metastatic muscle invasive bladder cancer.

Dr. Ansell on Combining CAR T-cell Therapy and Immunotherapy in Lymphomas

August 3rd 2017

Stephen M. Ansell, MD, PhD, chair of the Lymphoma Group at Mayo Clinic, discusses the possibility of blending immunotherapy agents with chimeric antigen receptor (CAR) T-cell therapy across lymphoma populations.

Dr. Bauml Discusses Immunotherapy Agents in Head and Neck Cancer

August 3rd 2017

Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses immunotherapy agents in head and neck cancer.

Dr. Atkins on Sequencing of Immunotherapy Combination Regimens

August 3rd 2017

Michael B. Atkins, MD, deputy director, Georgetown-Lombardi Comprehensive Cancer Center, professor of oncology and medicine, Georgetown University School of Medicine, discusses sequencing of immunotherapy combination regimens for patients with renal cell carcinoma (RCC).

Pembrolizumab Plus Epacadostat Active in RCC

August 2nd 2017

Primo N. Lara Jr, MD, discusses the KEYNOTE-037 pembrolizumab/epacadostat findings in patients with advanced RCC, and how the combination could change treatment in this population.

Dr. Balar on PD-L1 Testing for Urothelial Cancer

August 2nd 2017

Arjun V. Balar, MD, assistant professor of medicine, Division of Hematology and Oncology, Perlmutter Cancer Center, NYU Langone Medical Center, discusses PD-L1 testing and the development of biomarkers for PD-L1 antibodies for patients with urothelial carcinoma.

Dr. Nowakowski on the Potential Role of Immunotherapy in MCL

August 1st 2017

Grzegorz S. Nowakowski, MD, assistant professor of medicine at Mayo Clinic, discusses what potential immunotherapy agents have in the treatment landscape of mantle cell lymphoma (MCL).

FDA Approves Nivolumab for MSI-H or dMMR Colorectal Cancer

August 1st 2017

The FDA has granted an accelerated approval to nivolumab for the treatment of adult and pediatric patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.